Insider Selling: Bruker (NASDAQ:BRKR) VP Sells 7,000 Shares of Stock

January 14, 2026 by InsiderTrades.com

Key Points

Insider sale: VP Mark Munch sold 7,000 shares at about $55 on Jan. 12 for $385,000, reducing his position by 5.17% but still holding 128,443 shares (~$7.06M).
Shares slid roughly 4.7% amid intraday selloff coverage and the disclosed sale; the stock opened at $50.88, has a market cap of ~$7.73B and a one-year range of $28.53–$63.95, with a consensus analyst rating of Hold and an average price target of $52.29.
Q4 beat but mixed outlook: Bruker reported Q4 EPS of $0.45 (vs. $0.33 est.) and revenue of $860.5M (vs. $847.4M) but showed a negative net margin and set FY2025 EPS guidance of $1.85–1.90 versus analysts' ~2.69 EPS forecast, leaving some uncertainty.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) VP Mark Munch sold 7,000 shares of the company's stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the transaction, the vice president owned 128,443 shares in the company, valued at approximately $7,064,365. The trade was a 5.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Bruker Stock Down 4.7%

Shares of NASDAQ BRKR opened at $50.88 on Wednesday. The stock has a market capitalization of $7.73 billion, a P/E ratio of -318.00, a P/E/G ratio of 6.89 and a beta of 1.17. The company has a 50-day moving average price of $46.64 and a 200-day moving average price of $39.87. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $63.95. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.33 by $0.12. The company had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm's revenue was down .5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Investors of record on Monday, December 8th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker's payout ratio is presently -125.00%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its stake in shares of Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock worth $5,148,000 after purchasing an additional 9,501 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Bruker during the first quarter valued at $262,000. Goldman Sachs Group Inc. increased its position in Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock worth $61,162,000 after buying an additional 758,301 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Bruker by 2.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company's stock worth $15,285,000 after buying an additional 9,235 shares during the last quarter. Finally, Focus Partners Wealth raised its stake in shares of Bruker by 115.0% in the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company's stock valued at $469,000 after buying an additional 6,008 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Bruker

Here are the key news stories impacting Bruker this week:

Positive Sentiment: Bank of America kept a Buy rating on BRKR, citing solid Q4 momentum and reaffirmed 2026 targets — this supports upside case for the stock. TipRanks/BofA Report
Neutral Sentiment: Bruker presented at the 44th Annual J.P. Morgan Healthcare Conference (slides and transcript available) — useful for longer-term visibility on strategy and targets but not an immediate catalyst. Slides Transcript
Neutral Sentiment: Reported short-interest data appears anomalous (entries show zero and NaN values) — no clear signal from shorting activity based on the released figures.
Negative Sentiment: Market coverage: outlets are flagging a sharp intraday selloff and explaining drivers — coverage can amplify selling pressure. MSN: Why BRKR Shares Are Plunging
Negative Sentiment: An insider (VP Mark Munch) sold 7,000 shares at ~$55 each on Jan 12 — the disclosed sale (SEC Form 4) can be perceived negatively by some investors even though he still holds a large position. SEC Form 4
Negative Sentiment: Bruker updated Q4 FY25 guidance with revenue range listed at $965–$970M (slightly above consensus) but EPS guidance was left unclear/missing in the release — the lack of clear EPS guidance likely increased uncertainty and triggered selling.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Rothschild Redb raised shares of Bruker to a "strong-buy" rating in a report on Thursday, November 20th. Wells Fargo & Company raised their price target on shares of Bruker from $48.00 to $55.00 and gave the company an "overweight" rating in a research report on Monday, December 15th. Bank of America upped their price objective on shares of Bruker from $43.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, December 15th. TD Cowen lifted their target price on shares of Bruker from $42.00 to $53.00 and gave the stock a "hold" rating in a research report on Wednesday, January 7th. Finally, Redburn Partners set a $60.00 target price on Bruker in a research note on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $52.29.

Get Our Latest Research Report on Bruker

About Bruker

(Get Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.